Hepatocellular Carcinoma Drugs Global Market Report 2025

Description

Hepatocellular carcinoma drugs are medications designed for the treatment of primary liver cancer originating from hepatocytes, the primary type of liver cells. Hepatocellular carcinoma often develops in the context of chronic liver diseases, including chronic hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), or liver cirrhosis.

The main types of hepatocellular carcinoma drugs include brachytherapy and chemotherapy. Brachytherapy is a form of radiation therapy employed in cancer treatment, involving the precise placement of radioactive sources directly into or near the tumor site. Radioactive sources used in brachytherapy for hepatocellular carcinoma include iodine-125 and iridium-192. The various drug classes of hepatocellular carcinoma drugs encompass PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors, utilized in settings such as hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

The hepatocellular carcinoma drugs market research report is one of a series of new reports from The Business Research Company that provides hepatocellular carcinoma drugs market statistics, including hepatocellular carcinoma drugs industry global market size, regional shares, competitors with a hepatocellular carcinoma drugs market share, detailed hepatocellular carcinoma drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatocellular carcinoma drugs industry. This hepatocellular carcinoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from$1.16 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased disease incidence, advancements in cancer research, global healthcare infrastructure improvement, regulatory approvals, awareness and early diagnosis initiatives

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to targeted therapies advancements, increasing geriatric population, healthcare personalization trends, global expansion of treatment access. Major trends in the forecast period include access to innovative therapies, patient-centric care, regulatory advancements, drug resistance mitigation strategies, collaborative research initiatives.

The hepatocellular carcinoma drug market is expected to witness substantial growth in the coming years due to the increasing incidence of hepatocellular carcinoma (HCC), the most common form of liver cancer. HCC originates in hepatocyte cells, the main type of liver cells, and is often associated with hepatitis B or C infections and cirrhosis. The rising occurrence of HCC is driving the demand for effective drugs to treat the disease. According to a 2023 report by the American Cancer Society, the estimated new cases of liver cancer in females in the United States increased from 12,660 in 2022 to 13,230 in 2023, highlighting the need for advancements in hepatocellular carcinoma drugs.

The growth of the hepatocellular carcinoma drugs market is further propelled by the increasing prevalence of hepatitis, an inflammatory condition of the liver linked to chronic hepatitis B (HBV) and hepatitis C (HCV) infections. Chronic hepatitis infections often lead to liver cirrhosis, a precursor to HCC, emphasizing the importance of drugs addressing hepatocellular carcinoma. As of April 2022, the European Centre for Disease Prevention and Control reported a notable number of hepatitis cases in various countries, including the UK, the US, Israel, and Japan. This escalating prevalence of hepatitis is a significant factor driving the growth of the hepatocellular carcinoma drugs market.

Major companies in the market are focusing on developing laboratory-produced molecules, particularly monoclonal antibodies (mAb). Monoclonal antibodies are engineered to mimic the immune system's ability to combat pathogens. AstraZeneca's FDA approval for Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for hepatocellular carcinoma treatment is a notable example of such developments. Imfinzi, a human monoclonal antibody targeting PD-L1, and Imjudo, targeting CTLA-4, work synergistically to enhance the immune response against cancer cells.

Leading companies in the hepatocellular carcinoma drugs market are actively creating innovative products, including liver cancer medications, to cater to larger customer bases, boost sales, and enhance overall revenue. Drugs for liver cancer encompass a diverse range of pharmaceutical interventions aimed at treating and managing the disease. As an example, in October 2022, Eli Lilly and Company, a pharmaceutical firm based in the United States, announced the approval of Cyramza (ramucirumab) by the National Medical Products Administration (NMPA) for the treatment of hepatocellular carcinoma in China. Cyramza is the first novel medicine to receive approval following a specific evaluation in a biomarker-enriched population of hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) levels exceeding 400 ng/ml. The study results in Chinese patients demonstrated a consistent efficacy and safety profile comparable to the global population. This approval is expected to positively impact the clinical approach to liver cancer in China by introducing a new and effective treatment option for advanced HCC among Chinese patients.

In August 2023, Novartis AG, a pharmaceutical company based in Switzerland, completed the acquisition of Chinook Therapeutics Inc. for a deal valued at $3.2 billion. Through this strategic acquisition, Novartis aims to leverage the combined resources and expertise to advance the development of promising treatments for individuals with rare and severe chronic kidney diseases. The integration of the Chinook team is anticipated to bolster Novartis in expanding its portfolio related to renal conditions and contribute to its ongoing commitment to redefine medicine. Chinook Therapeutics Inc., headquartered in the United States, specializes in developing treatments for rare and severe chronic kidney disorders, including hepatocellular carcinoma (HCC).

Major companies operating in the hepatocellular carcinoma drugs market include AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatocellular carcinoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hepatocellular carcinoma drug market consists of revenues earned by entities by providing surgery, radiofrequency ablation, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatocellular carcinoma drug market also includes sales of cabozantinib, ramucirumab and pembrolizumab drugs used for the treatment of hepatocellular carcinoma drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatocellular Carcinoma Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatocellular carcinoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatocellular carcinoma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatocellular carcinoma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Brachytherapy; Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors; Tyrosine Kinase Inhibitors
3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
Subsegments:
1) By Brachytherapy: Radioactive Seed Implants; Balloon-Activated Brachytherapy; SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy; Targeted Therapy Agents; Combination Chemotherapy Regimens; Adjuvant Chemotherapy
Companies Mentioned: AbbVie Inc.; Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Eisai Co.Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24194

1. Executive Summary

2. Hepatocellular Carcinoma Drugs Market Characteristics

3. Hepatocellular Carcinoma Drugs Market Trends And Strategies

4. Hepatocellular Carcinoma Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hepatocellular Carcinoma Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatocellular Carcinoma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatocellular Carcinoma Drugs Market Growth Rate Analysis
5.4. Global Hepatocellular Carcinoma Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatocellular Carcinoma Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatocellular Carcinoma Drugs Total Addressable Market (TAM)

6. Hepatocellular Carcinoma Drugs Market Segmentation

6.1. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Brachytherapy
Chemotherapy
6.2. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-1/PD-L1 Inhibitors
Tyrosine Kinase Inhibitors
6.3. Global Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers
6.4. Global Hepatocellular Carcinoma Drugs Market, Sub-Segmentation Of Brachytherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Radioactive Seed Implants
Balloon-Activated Brachytherapy
SIRT (Selective Internal Radiation Therapy)
6.5. Global Hepatocellular Carcinoma Drugs Market, Sub-Segmentation Of By Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systemic Chemotherapy
Targeted Therapy Agents
Combination Chemotherapy Regimens
Adjuvant Chemotherapy

7. Hepatocellular Carcinoma Drugs Market Regional And Country Analysis

7.1. Global Hepatocellular Carcinoma Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatocellular Carcinoma Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatocellular Carcinoma Drugs Market

8.1. Asia-Pacific Hepatocellular Carcinoma Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatocellular Carcinoma Drugs Market

9.1. China Hepatocellular Carcinoma Drugs Market Overview
9.2. China Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatocellular Carcinoma Drugs Market

10.1. India Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatocellular Carcinoma Drugs Market

11.1. Japan Hepatocellular Carcinoma Drugs Market Overview
11.2. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatocellular Carcinoma Drugs Market

12.1. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatocellular Carcinoma Drugs Market

13.1. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatocellular Carcinoma Drugs Market

14.1. South Korea Hepatocellular Carcinoma Drugs Market Overview
14.2. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatocellular Carcinoma Drugs Market

15.1. Western Europe Hepatocellular Carcinoma Drugs Market Overview
15.2. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatocellular Carcinoma Drugs Market

16.1. UK Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatocellular Carcinoma Drugs Market

17.1. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatocellular Carcinoma Drugs Market

18.1. France Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatocellular Carcinoma Drugs Market

19.1. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatocellular Carcinoma Drugs Market

20.1. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatocellular Carcinoma Drugs Market

21.1. Eastern Europe Hepatocellular Carcinoma Drugs Market Overview
21.2. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatocellular Carcinoma Drugs Market

22.1. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatocellular Carcinoma Drugs Market

23.1. North America Hepatocellular Carcinoma Drugs Market Overview
23.2. North America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatocellular Carcinoma Drugs Market

24.1. USA Hepatocellular Carcinoma Drugs Market Overview
24.2. USA Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatocellular Carcinoma Drugs Market

25.1. Canada Hepatocellular Carcinoma Drugs Market Overview
25.2. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatocellular Carcinoma Drugs Market

26.1. South America Hepatocellular Carcinoma Drugs Market Overview
26.2. South America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatocellular Carcinoma Drugs Market

27.1. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatocellular Carcinoma Drugs Market

28.1. Middle East Hepatocellular Carcinoma Drugs Market Overview
28.2. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatocellular Carcinoma Drugs Market

29.1. Africa Hepatocellular Carcinoma Drugs Market Overview
29.2. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatocellular Carcinoma Drugs Market Competitive Landscape And Company Profiles

30.1. Hepatocellular Carcinoma Drugs Market Competitive Landscape
30.2. Hepatocellular Carcinoma Drugs Market Company Profiles
- 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eisai Co.Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatocellular Carcinoma Drugs Market Other Major And Innovative Companies

31.1. Eli Lilly and Company
31.2. Johnson & Johnson
31.3. Merck & Co. Inc.
31.4. Novartis AG
31.5. Pfizer Inc.
31.6. Takeda Pharmaceutical Company Limited
31.7. Teva Pharmaceutical Industries Ltd.
31.8. F. Hoffmann-La Roche Ltd
31.9. Gilead Sciences Inc.
31.10. Exelixis Inc.
31.11. Ipsen Pharma Biotech SAS
31.12. AstraZeneca plc
31.13. BeiGene Ltd.
31.14. Ono Pharmaceutical Co. Ltd.
31.15. Roche Holdings AG

32. Global Hepatocellular Carcinoma Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatocellular Carcinoma Drugs Market

34. Recent Developments In The Hepatocellular Carcinoma Drugs Market

35. Hepatocellular Carcinoma Drugs Market High Potential Countries, Segments and Strategies

35.1 Hepatocellular Carcinoma Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatocellular Carcinoma Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatocellular Carcinoma Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer